Philadelphia Pharmaceuticals Company (ASE:PHIL)

ASE:PHIL Income Statement

Financials in millions JOD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	9.17	8.76	8.4	8.42	6.6
Revenue Growth (YoY)	4.64%	4.25%	-0.12%	27.48%	-13.77%
Cost of Revenue	4.66	4.64	4.4	4.51	3.47
Gross Profit	4.51	4.12	4	3.91	3.13
Selling, General & Admin	2.52	2.3	2.21	2.59	2.41
Research & Development	0.45	0.42	0.44	0.22	-
Operating Expenses	2.97	2.72	2.65	2.81	2.41
Operating Income	1.54	1.4	1.35	1.1	0.72
Interest Expense	-0.29	-0.35	-0.34	-0.24	-0.23
Other Non Operating Income (Expenses)	0.03	-0	0	0	0.01
EBT Excluding Unusual Items	1.27	1.04	1.02	0.87	0.49
Pretax Income	1.27	1.04	1.02	0.87	0.49
Income Tax Expense	0.27	0.22	0.21	0.16	0.08
Net Income	1.01	0.82	0.81	0.7	0.41
Net Income to Common	1.01	0.82	0.81	0.7	0.41
Net Income Growth	22.35%	1.77%	15.13%	70.91%	189.48%
Shares Outstanding (Basic)	8	8	8	8	8
Shares Outstanding (Diluted)	8	8	8	8	8
EPS (Basic)	0.13	0.11	0.11	0.09	0.05
EPS (Diluted)	0.13	0.11	0.11	0.09	0.05
EPS Growth	22.35%	1.77%	15.13%	70.91%	189.49%
Free Cash Flow	1.15	1.53	1.03	1.94	2.94
Free Cash Flow Per Share	0.15	0.20	0.14	0.26	0.39
Dividend Per Share	-	0.070	0.070	0.060	0.060
Dividend Growth	-	-	16.67%	-	-
Gross Margin	49.16%	47.03%	47.64%	46.42%	47.47%
Operating Margin	16.77%	15.94%	16.12%	13.05%	10.90%
Profit Margin	10.96%	9.38%	9.60%	8.33%	6.21%
Free Cash Flow Margin	12.58%	17.43%	12.30%	23.07%	44.57%
EBITDA	2.07	1.67	1.65	1.22	0.88
EBITDA Margin	22.59%	19.08%	19.62%	14.48%	13.32%
D&A For EBITDA	0.53	0.28	0.29	0.12	0.16
EBIT	1.54	1.4	1.35	1.1	0.72
EBIT Margin	16.77%	15.94%	16.12%	13.05%	10.90%
Effective Tax Rate	21.00%	21.03%	21.02%	19.00%	16.94%
Advertising Expenses	-	-	-	0.21	0.2

Source: S&P Global Market Intelligence. Standard template. Financial Sources.